Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/26/2003EP1363948A1 Polypeptide of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids coding therefor and use thereof
11/26/2003EP1363943A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/26/2003EP1363942A2 Polypeptide from a hdm2 protein specific murine alpha/beta t-cell receptors, nucleic acids coding for the above and use thereof
11/26/2003EP1363940A1 Tumour peptide antigen produced from human mdm2 proto-oncogene
11/26/2003EP1363938A2 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
11/26/2003EP1363933A2 Sterol derivatives, liposomes comprising sterol derivatives and method for loading liposomes with active substances
11/26/2003EP1363932A2 Amphoteric sterols and the use thereof
11/26/2003EP1363927A2 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
11/26/2003EP1363925A1 Macrolide antibiotics
11/26/2003EP1363924A1 Avilamycin derivatives
11/26/2003EP1363920A1 Modified psma ligands and uses related thereto
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363912A1 Novel substituted imidazotriazinones
11/26/2003EP1363911A1 Synthesis of temozolomide and analogs
11/26/2003EP1363910A2 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
11/26/2003EP1363909A2 Tricyclic androgen receptor modulator compounds
11/26/2003EP1363908A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM
11/26/2003EP1363907A2 Heterocycle carboxamides as antiviral agents
11/26/2003EP1363906A2 Heterocyclic inhibitors of erk2 and uses thereof
11/26/2003EP1363904A1 Pyrazoles as tgf inhibitors
11/26/2003EP1363903A1 Indole derivatives and their use as gnrh antagonists
11/26/2003EP1363902A1 Chemical compounds
11/26/2003EP1363901A1 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
11/26/2003EP1363900A1 Isoindole-imide compounds as tnf-inhibitors
11/26/2003EP1363899A1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
11/26/2003EP1363898A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363897A2 Antagonists of mcp-1 function and methods of use thereof
11/26/2003EP1363892A1 Stable pharmaceutical form of an anticancer drug
11/26/2003EP1363891A2 Anthrone derivatives and their use as jnk inhibitors
11/26/2003EP1363890A2 Melanocortin-4 receptor binding compounds and methods of use thereof
11/26/2003EP1363888A2 Therapeutic acridone and acridine compounds
11/26/2003EP1363887A1 Substituted quinolinecarboxamides as antiviral agents
11/26/2003EP1363885A1 Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
11/26/2003EP1363884A2 Pyridine-substituted benzanilides as potassium ion channel openers
11/26/2003EP1363882A1 3-(3-amidinophenyl)-5- ( 1-(1-(-iminoethyl)-4-piperidyl amino)methyl]benzoic acid dihydrochloride and process for preparing the same
11/26/2003EP1363881A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
11/26/2003EP1363880A1 Synthesis for the preparation of compounds for screening as potential tubulin binding agents
11/26/2003EP1363879A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
11/26/2003EP1363877A2 Benzophenones as inhibitors of reverse transcriptase
11/26/2003EP1363876A1 Glucocorticoid receptor modulators
11/26/2003EP1363875A2 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity
11/26/2003EP1363874A2 Tryptase inhibitors
11/26/2003EP1363873A2 Peptide deformylase inhibitors
11/26/2003EP1363705A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
11/26/2003EP1363704A2 Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor
11/26/2003EP1363702A1 Methods of inhibiting kinases
11/26/2003EP1363674A2 Agents and methods for treating pain
11/26/2003EP1363671A2 Water-soluble compositions of bioactive lipophilic compounds
11/26/2003EP1363670A1 Polynucleotide formulation for enhanced intracellular transfer
11/26/2003EP1363669A2 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
11/26/2003EP1363668A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/26/2003EP1363667A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
11/26/2003EP1363654A2 Fab i and inhibition of apicomplexan parasites
11/26/2003EP1363653A2 Methods and compositions for enhancing angiogenesis
11/26/2003EP1363652A2 Way to obtain an extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it
11/26/2003EP1363651A1 Herbal compositions useful as chemopreventive and therapeutic agents
11/26/2003EP1363648A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
11/26/2003EP1363644A2 Modulation of gsk-3beta activity and its different uses
11/26/2003EP1363643A2 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
11/26/2003EP1363642A2 Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
11/26/2003EP1363641A1 Progestin co-micronized with a surfactant, pharmaceutical composition comprising same, methods for making same and uses thereof
11/26/2003EP1363640A2 Nucleic acid derivatives
11/26/2003EP1363639A1 PYRROLO 2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
11/26/2003EP1363638A2 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
11/26/2003EP1363637A1 Pyrimidine compounds and methods for making and using the same
11/26/2003EP1363636A1 A method for the treatment of heart failure
11/26/2003EP1363635A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
11/26/2003EP1363634A2 Compounds for the treatment of addictive disorders
11/26/2003EP1363633A1 A process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
11/26/2003EP1363632A1 Receptor selective cannabimimetic aminoalkylindoles
11/26/2003EP1363631A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363630A2 Kappa opioid receptor ligands
11/26/2003EP1363629A1 Kappa opioid receptor ligands
11/26/2003EP1363628A2 Drugs for sex dysfunctions
11/26/2003EP1363627A2 Treatment of solid tumours with rapamycin derivatives
11/26/2003EP1363626A1 Antifungal remedy formulation for external application
11/26/2003EP1363625A1 Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
11/26/2003EP1363624A2 Fluoro oxindole derivatives as modulators of kcnq potassium channels
11/26/2003EP1363623A2 Peptide deformylase inhibitors
11/26/2003EP1363622A1 Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
11/26/2003EP1363621A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
11/26/2003EP1363620A2 Use of fredericamycin and its derivatives in the treatment of pin1-associated states
11/26/2003EP1363619A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
11/26/2003EP1363618A1 Pharmaceutical composition for treating multiple sclerosis
11/26/2003EP1363617A1 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damaging cutaneous tissue
11/26/2003EP1363616A1 Carboxylic acid such as citric acid for disinfecting or enhancing the production of blood products such as plasma, cryoprecipitate or/and platelet
11/26/2003EP1363615A1 Preservation of body protein
11/26/2003EP1363614A2 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
11/26/2003EP1363613A2 Use of rhein for preparing a medicine for treating a high rate of il-1
11/26/2003EP1363612A2 Peptide deformylase inhibitors
11/26/2003EP1363611A1 Retinoid hepatitis therapy
11/26/2003EP1363610A2 Carotenoids as anti-hypertension agents
11/26/2003EP1363609A2 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation
11/26/2003EP1363608A1 Treatment of sleep disturbances
11/26/2003EP1363606A1 Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders
11/26/2003EP1363605A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
11/26/2003EP1363604A2 Pharmaceutical formulation
11/26/2003EP1363602A1 Local anesthetic, and method of use
11/26/2003EP1363601A2 Amphoteric liposomes and the use thereof
1 ... 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 ... 7860